Shang Xue-jun, Huang Yu-feng, Shao Yong, Xue Xiao-tong, Guan Feng-gang, Li Guang, Wang Jie
Department of Andrology, Nanjing General Hospital of Nanjing Command, PLA, Nanjing, Jiangsu, China.
Zhonghua Nan Ke Xue. 2006 Apr;12(4):371-3.
To explore the effectiveness of Longjintonglin capsule in treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
One hundred and thirty-six patients accorded with the demands of chronic prostatitis type III of National Institute of Health (NIH), among them there were 84 cases of chronic prostatitis type IIIA and 52 cases of type IIIB. All of the patients accepted oral Longjintonglin capsule for 3 tablets, 3 times per day, for 3 months. NIH- chronic prostatitis symptom index (NIH-CPSI) and counting leukocytes in expressed prostatic secretions (EPS) were used as target to evaluate the effectiveness.
One hundred and thirty-one cases accomplished treatment, in which there were 81 cases of type IIIA, and 50 cases of type IIIB. Overall scores of NIH-CPSI before and after treatment were(24.8 +/- 5.6) and (13.3 +/- 6.8) points respectively, which dropped significantly (average 11.5 points), (P < 0.01). The symptom scores before and after treatment were (15.4 +/- 4.3) and (8.7 +/- 3.9) respectively, which also decreased significantly (average 6.7 points), (P <0.01). The scores for quality of life before and after treatment were (9.4 +/- 3.7) and (4.6 +/- 2.7) respectively, which dropped significant (average 4.8 points) (P < 0.01). The leukocytes counts before and after treatment in patients with CP/CPPs type IIIA were (21.7 +/- 14.5)/HP and (8.8 +/- 12.6)/HP, respectively. Twenty-four cases(18.3%) got cured, 41 cases (31.3%) notable effect, 40 cases (30.5%) some effect, 26 cases (19.8%) no effect, and total effective rate was 80.1%. No apparent side effect was observed in all patients accepted treatment, especially for their kidney and hepatic function.
Longjintonglin capsule was a safe and effective medicine in treatment of CP/CPPS without significant side effect.
探讨龙金通淋胶囊治疗慢性前列腺炎/慢性盆腔疼痛综合征（CP/CPPS）的疗效。
136例符合美国国立卫生研究院（NIH）慢性前列腺炎Ⅲ型诊断标准的患者，其中ⅢA型84例，ⅢB型52例。所有患者口服龙金通淋胶囊，每次3片，每日3次，疗程3个月。以NIH慢性前列腺炎症状指数（NIH-CPSI）及前列腺按摩液（EPS）白细胞计数为疗效评价指标。
131例完成治疗，其中ⅢA型81例，ⅢB型50例。治疗前后NIH-CPSI总分分别为（24.8±5.6）分和（13.3±6.8）分，显著下降（平均11.5分），（P<0.01）。症状评分治疗前后分别为（15.4±4.3）分和（8.7±3.9）分，也显著降低（平均6.7分），（P<0.01）。生活质量评分治疗前后分别为（9.4±3.7）分和（4.6±2.7）分，显著下降（平均4.8分）（P<0.01）。ⅢA型CP/CPPs患者治疗前后白细胞计数分别为（21.7±14.5）/HP和（8.8±12.6）/HP。治愈24例（18.3%），显效41例（31.3%），有效40例（30.5%），无效26例（19.8%），总有效率80.1%。所有接受治疗的患者均未观察到明显副作用，尤其是对肝肾功能无明显影响。
龙金通淋胶囊治疗CP/CPPS安全有效，无明显副作用。
